Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
HIV
adherence
adverse events
completion
postexposure prophylaxis
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
14 02 2020
14 02 2020
Historique:
received:
10
03
2019
accepted:
26
06
2019
pubmed:
6
12
2019
medline:
7
1
2021
entrez:
6
12
2019
Statut:
ppublish
Résumé
We evaluated an elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis. The completion rate and adherence were good, and the tolerance was acceptable; no seroconversion was observed. We confirm that this regimen could be appropriate for postexposure prophylaxis. NCT02998320.
Identifiants
pubmed: 31804669
pii: 5525174
doi: 10.1093/cid/ciz577
doi:
Substances chimiques
Anti-HIV Agents
0
Drug Combinations
0
Quinolones
0
Tablets
0
elvitegravir
4GDQ854U53
Tenofovir
99YXE507IL
tenofovir alafenamide
EL9943AG5J
Emtricitabine
G70B4ETF4S
Adenine
JAC85A2161
Cobicistat
LW2E03M5PG
Alanine
OF5P57N2ZX
Banques de données
ClinicalTrials.gov
['NCT02998320']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
943-946Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.